Breckenridge Pharmaceutical, Inc: Duloxetine Delayed-Release Capsules, USP, 30mg
Recall reason: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit. Recalled by Breckenridge Pharmaceutical, Inc. Distribution: US Nationwide.. Classification (Class II — potential health risk). Affected lots/NDC/dates: 220265: Exp. Feb 2025 220088: Exp. Nov 2024 220267: Exp. Feb 2025 220256: Exp. Feb 2025 220225: Exp. Jan 2025 220269: Ex. Return the recalled medication to the pharmacy where you purchased it for a full refund of the purchase price.
📬 Get email alerts for new Product Recalls & Refunds
Free — we'll email you when new matching opportunities appear. No spam, unsubscribe anytime.
New here? Here's how Reward Opportunity works:
🔔 More Product Recalls & Refunds
Product recalls offering refunds, replacements, or repairs to consumers who purchased the item.
Browse all product recalls & refunds →Not just this one — find everything you qualify for
Our AI scans 8,000+ bounties, settlements, grants, recalls, and paid studies against your profile to rank what you can actually claim.
Get My Free Match Report